Shares of Evommune, Inc. (EVMN) are surging about 51 percent on Tuesday morning trading following the announcement of positive top-line data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis.
The company's stock is currently trading at $25.81, up 51.80 percent or $8.65, over the previous close of $16.99 on the New York Stock Exchange. It has traded between $13.89 and $30.00 in the past one year.
The study met its primary efficacy endpoint at Week 12 and demonstrated rapid, statistically significant improvements across multiple time points.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.